RC18 160 mg plus MTX

BIOLOGICAL2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Moderate and Severe RheumatoId ArthritisModerate and Severe Rheumatoid Arthritis

Phase 2

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

TerminatedNCT02882087

RemeGen Co., Ltd.Moderate and Severe Rheumatoid Arthritis

Start: 2015-10-31End: 2019-02-25Target: 60Updated: 2019-04-03

Phase 3

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

CompletedNCT03016013

RemeGen Co., Ltd.Moderate and Severe RheumatoId Arthritis

Start: 2017-03-29End: 2022-12-29Updated: 2024-09-26